Furthermore, anti-CD4 monoclonal antibody therapy for SLE significantly reduced the incidence of vasculitis, and glomerulonephritis, and significantly lowered the levels of antinuclear antibody, total IgG, and anti-dsDNA33. This evidence concerns the gene CD4 and systemic lupus erythematosus.